<DOC>
	<DOCNO>NCT01603277</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy single dose level KB003 subject inadequately control asthma .</brief_summary>
	<brief_title>Effect KB003 Subjects With Asthma Inadequately Controlled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key A diagnosis asthma establish least 2 year Symptomatic asthma define Juniper Asthma Control Questionnaire Symptomatic asthma despite stable treatment inhaled corticosteroid fluticasone budesonide , corticosteroid , least 12 week Currently receive inhale longacting beta agonist ( LABA ) previously document LABA intolerability lack responsiveness At least 2 exacerbation ( 6 ) previous 12 month require systemic corticosteroid least double daily oral dose Key Acute asthma worsening ( require emergency room visit , hospitalization , urgent care , physician visit , change asthma medication ) low respiratory tract infection require use antibiotic , within 4 week prior Screening Visit . History lifethreatening asthma admission intensive care unit require use mechanical ventilation within past 12 month Use immunosuppressive immunomodulatory agent within 12 week investigational agent within 4 week prior Screening Visit History cardiovascular , neurological , hepatic , renal condition History smoking within past 12 month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Moderate-to-Severe Asthma</keyword>
</DOC>